The first pharmacological option based on monoclonal antibodies for the prevention of Covid-19 in frail patients is available in Italy.
The pharmaceutical company AstraZeneca announces that the Italian Medicines Agency (Aifa) has approved the use of the combination of two long-acting monoclonal antibodies (tixagevimab and cilgavimab) to prevent Covid-19 symptoms, before exposure to the virus, in people at high risk.
The combination reduces the risk of developing symptomatic disease by 83% for at least six months after a single dose.
The publication in the Gazzetta dates back to the end of January.